Skip to main
OPCH

OPCH Stock Forecast & Price Target

OPCH Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 56%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Option Care Health Inc demonstrated robust financial performance with a 6.3% increase in gross margin dollar generation during the quarter, indicating effective cost management and operational efficiency. The company's commitment to shareholder value was evidenced by a significant stock repurchase program, which increased from previous quarters, alongside a 10% growth in its chronic therapy business. Additionally, Option Care Health's enhanced financial guidance for FY/25, coupled with strong cash flow generation and the potential for improved margins through increased utilization, positions the company favorably for sustained revenue growth.

Bears say

Option Care Health Inc. faces a negative outlook primarily due to rising general and administrative (G&A) expenses as a percentage of revenue, which is expected to decline only gradually over several quarters. The company currently relies heavily on its largest customer, which constitutes 14% of its revenue, making it vulnerable to significant financial impacts in the event of a customer loss. Additionally, anticipated gross profit headwinds related to the Stelara product and its biosimilars are projected to reach between $25 million to $35 million, likely limiting both EBITDA margin expansion and overall profitability in the near term.

OPCH has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 56% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Option Care Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Option Care Health (OPCH) Forecast

Analysts have given OPCH a Buy based on their latest research and market trends.

According to 9 analysts, OPCH has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Option Care Health (OPCH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.